Niraparib
- Generic Name
- Niraparib
- Brand Names
- Zejula
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O
- CAS Number
- 1038915-60-4
- Unique Ingredient Identifier
- HMC2H89N35
- Background
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...
- Indication
Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
- Associated Therapies
- Maintenance therapy
Niraparib + Dostarlimab + RT in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT04409002
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Jihong Liu
- Target Recruit Count
- 40
- Registration Number
- NCT04376073
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Ulrik Lassen
- Target Recruit Count
- 300
- Registration Number
- NCT04341181
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Trisha Wise-Draper
- Target Recruit Count
- 23
- Registration Number
- NCT04313504
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 20
- Registration Number
- NCT04284852
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04267939
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 14
- Registration Number
- NCT04240106
- Locations
- 🇪🇸
Centro Oncologico de Galicia, A Coruña, Spain
🇪🇸Hospital Universitario Virgen de la Victoria, Málaga, Spain
🇪🇸Hospital Clínic i provincial de Barcelona, Barcelona, Spain
Niraparib/TTFields in GBM
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 30
- Registration Number
- NCT04221503
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT04217798
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04194554
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Cornell University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.